



Sperm count affects cumulative birth rate of assisted reproduction cycles in relation to ovarian response

Carlotta Zacà¹ · Giovanni Coticchio¹ · Nicoletta Tarozzi¹ · Marco Nadalini¹ · Cristina Lagalla¹ · Andrea Garolla² · Andrea Borini¹

Received: 10 January 2020 / Accepted: 1 May 2020 / Published online: 13 May 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

Purpose To explore the possible influence of sperm quality, as assessed by prewash total sperm count (TSC), on cumulative success rates in assisted reproduction cycles.

Methods Retrospective study carried out in private IVF centre. Seven hundred sixty-five couples undergoing complete ICSI cycles, i.e. whose all embryos were transferred or disposed of. Couples were characterised by male infertility and female age younger than 36 years. Couples with a combination of female and male infertility factors were excluded. The primary outcome measure was cumulative live birth rate. Secondary outcomes were cumulative pregnancy and miscarriage rates. No specific interventions were made.

Results Higher TSC values have a positive impact on cumulative success rates in cycles characterised by few retrieved oocytes (1 to 5), while does not influence the outcome of cycles with a normal (6 to 10) or high (> 10) number of retrieved oocytes.

Conclusions The study highlights the importance of sperm quality for the efficacy of assisted reproduction treatments. This influence may remain relatively cryptic in association with normal or high ovarian response, but emerge decisively in cases of reduced ovarian response, suggesting a relationship between ovarian response and oocyte ability to compensate for paternal-derived deficiencies.

Keywords Sperm count · Ovarian stimulation · Assisted reproduction · Pregnancy · Live birth

Introduction

The clinical outcome of assisted reproduction technology (ART) treatments is influenced by a myriad of intrinsic and extrinsic factors. Crucially, oocyte, but not sperm, developmental competence is largely jeopardised by chromosomal aneuploidy. Sustained rates of aneuploidy are in fact observed at all maternal ages, unfortunately with an exponential increase after the age of 35 years [1, 2]. For such a reason, the

female gamete is recognised as the single most important factor affecting the ability of the preimplantation embryo to implant and develop to term, in vitro as well as in vivo [3]. Oocyte legacy has therefore overshadowed the perception of sperm role in embryogenesis and, more generally, reproduction. However, sperm actively participates in the genetic, epigenetic and cellular make-up of the embryo [4, 5]. A major part of sperm function unfolds at fertilization. This emerged rather clearly from the early history of ART when, in the absence of effective micromanipulation approaches, in vitro fertilization (IVF) was almost unachievable in cases of very severe male factor infertility or, worse, azoospermia. The advent of ICSI marked an epochal progress in the treatment of such cases [6]. With ICSI, in principle only, very few motile sperm are needed to maximise the generation of embryos from a cohort of oocytes, with obvious implications for treatment success [7]. However, the disarming ease by which ICSI overcomes otherwise untreatable sperm/seminal dysfunctions has generated a paradox. The male gamete has been progressively perceived by many fertility specialists as an element essential to compose a biparental zygote genome, but with little, if any,

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s10815-020-01807-5>) contains supplementary material, which is available to authorized users.

✉ Giovanni Coticchio
giovanni.coticchio@nove.baby

¹ 9.baby - Family and Fertility Center, via Dante 15,
40125 Bologna, Italy

² Unit of Andrology and Reproductive Medicine, Department of
Medicine, University of Padova, Padova, Italy

role in developmental processes before and after implantation. Consistent with this notion, purely male factor infertility cases are believed to be associated with a favourable clinical outcome after ART treatment [8]. Such a prognostic prediction has some rationale for the above explained dominant role of the oocyte in development. Nevertheless, it is largely based on outcome measures, e.g. implantation rates and pregnancy rates in fresh embryo transfers (ET), that by definition are inadequate to express the reproductive outcome of an entire cohort of oocytes derived from a single cycle of treatment. Hence, especially in situations in which a specific factor is suspected to have a significant impact on embryo developmental competence and ultimately reproductive outcome, broader, more comprehensive outcome measures should be adopted to appraise clinical success. From intense debates stirred across decades, cumulative live birth rate (CLBR) per treatment cycle has emerged as one of the most reliable and inclusive quantitative assessments by which clinical outcome can be expressed in ART [9–12].

In this retrospective study, we explored the possible influence of sperm quality on CLBR. To this end, we focused on the specific impact of prewash total sperm count (TSC), a parameter adopted because previously described being crucially associated with male fecundity, infertility and health [13]. Importantly, and specific to this study, TSC was observed in dependence of different patterns of ovarian response to hormone stimulation in young patients. Overall, the study data indicate that, while TSC is an important determinant of cumulative clinical success, its relative impact depends on ovarian response, suggesting new hypotheses on the mutual interaction between the quality of male and female gametes in the establishment of a viable pregnancy.

Materials and methods

Study population and groups

Reported data concern a retrospective cohort study carried out between January 2009 and December 2013 on 765 couples undergoing complete ICSI cycles, i.e. whose all embryos were transferred or disposed of. Pregnancy rates were calculated in relation to the number of started cycles. Approval for the study was obtained from the local Institutional Review Board. Informed consent was obtained from selected patients.

Couples included were characterised by male infertility diagnosis and female age younger than 36 years. Couples with a combination of female and male infertility factors were excluded. The cohort was grouped according to male partner's TSC into five groups: (1) $< 0.1 \times 10^6$ (189/765 cycles, 24.7%); (2) 0.1×10^6 to 1×10^6 (144/765 cycles, 18.8%); (3) 1×10^6 to 5×10^6 (150/765 cycles, 19.6%); (4) 5×10^6 up to 10×10^6

(103/765 cycles, 13.5%); (5) 10×10^6 to 39×10^6 TSC, (179/765 cycles, 23.4%).

These TSC intervals were identified on the basis of collective information or experience; we have chosen 39 million sperm total per ejaculate as maximum because the WHO manual for sperm analysis indicates this value as cut-off below which a semen sample is defined as oligospermic. In men with lowest TSC, the percentage of motile sperm was 19%, while in those with highest TSC this value was 29%. Groups were also analysed according to the number of oocytes retrieved and therefore, indirectly, ovarian response. We chose the intervals of 1–5, 6–10, and > 10 because, on the basis of existing literature, represent cases of poor, average, and good/high ovarian response. Preimplantation genetic testing (PGT) treatments and cycles in which spermatozoa were recovered surgically were excluded from this study.

Semen analysis and preparation

Semen samples were collected after 3–5 days of sexual abstinence by masturbation on the day of oocyte pick-up (OPU). After liquefaction for 30 min, semen samples were analysed, and volume, concentration, motility, agglutination, presence of round cells and morphology were evaluated before semen preparation according to the World Health Organization guidelines [13]. Sperm count were evaluated with the use of counting chambers improved Neubauer (IMN).

On the day of OPU, fresh sperm samples were prepared using a discontinuous PureSperm gradient (Nidacon, Flöjelbergsgatan, Sweden), and subsequently, the bottom fraction was aspirated and washed 10 min as previously described [14].

Sperm sample was layered upon a 40:80% PureSperm density gradient and processed by centrifugation at 600 g for 15 min and washed in 2 mL of sperm culture medium (PureSperm wash; Nidacon). The 40:80% PureSperm gradient volumes were changed according to the total number of motile spermatozoa as previously described [15]. After sperm preparation, a second evaluation of concentration, morphology and motility was carried out.

Ovarian stimulation, oocyte and embryo handling procedures

Ovarian stimulation and oocyte retrieval were carried out as previously described [16]. In women, follicular stimulation was performed with highly purified FSH (IBSA, Lodi, Italy) with starting dose ranging from 100 to 300 IU per day, according to hormonal and anthropometric parameters. OPU was performed 35–36 h after induction of final oocyte maturation with hCG administration (Gonasi; Amsa, Rome, Italy), via transvaginal ultrasound-guided aspiration. After 2 h from oocyte retrieval, cumulus cells were removed from companion oocytes [17]. Denuded oocytes were then assessed for nuclear

status and oocytes showing the extrusion of the first polar body were considered mature and used for ICSI as previously described [18]. Fertilization was assessed 16–18 h after insemination. Oocytes displaying two pronuclei and a second polar body were considered to be normally fertilised and cultured further. The embryos obtained were then cultured and transferred and/or cryopreserved until day 3 at cleavage stage. The number of transferred embryos was decided according to patient needs and national guidelines. Embryos were cryopreserved using a Kitazato vitrification protocol (BioPharma Co., Japan) with a closed system device (HSV straw, Cryo Bio System, France) as previously described [11]. Vitrification and warming procedures were carried out as previously described by Cobo et al. [19]. Subsequent frozen embryo transfer (FET) was performed in a supplemented cycle. In supplemented FET cycles, estrogen (Climara, Bayer) and vaginal progesterone (Crinone, Merck Serono) were administered in a sequential regimen aimed at mimicking the endocrine exposure of the endometrium in the physiologic cycle. Assessment of clinical pregnancy was achieved by ultrasound detection of the gestational sac and visualisation of foetal heartbeat. Miscarriage was defined as pregnancy loss after ultrasound confirmation of embryo implantation and detection of foetal heartbeat. Live birth was defined as the birth of at least one newborn after 24 weeks' gestation that exhibited signs of viability.

Statistical analysis

Continuous data were presented as absolute values, mean \pm SD. The comparison between different study groups, with regard to maternal age and number of oocytes retrieved was carried out using ANOVA test to evaluate the statistical significance of differences among age groups and oocytes retrieved. Categorical variables were presented as absolute values and percentages. The chi square test was used to compare cumulative clinical pregnancy, miscarriage and cumulative live birth rates. The primary outcome measure was cumulative live birth rate, while the secondary outcomes were cumulative pregnancy and miscarriage rate. Differences in outcome measures between groups were compared using the chi squared test. P values < 0.05 were considered to be statistically significant or highly significant if < 0.01 .

Results

Data were collected from 765 completed stimulation cycles, i.e. in which all embryos were transferred in fresh or frozen ET or disposed of, if deemed non-viable. Treatments of women older than 35 were not included to minimize the well-documented maternal age effect on treatment outcome. In a preliminary analysis, cycles were divided into five groups according to TSC values (expressed in millions): i.e. $\leq 0.1 \times 10^6$,

10^6 , $> 0.1 \times 10^6$ to 1×10^6 , $> 1 \times 10^6$ to 5×10^6 , $> 5 \times 10^6$ to 10×10^6 , $> 10 \times 10^6$ to 39×10^6 (Table 1). Such groups were identified according to TSC values discussed in the World Health Organization guidelines [13]. Thirty-five cycles (4.6%) were interrupted since no embryos for transfer or cryopreservation were obtained. Mean age and number of retrieved oocytes were comparable among groups. The mean number of embryos across the different TSC groups was also similar ($P = 0.066$). Cumulative pregnancy rates (CPR) were progressively higher with increasing TSC, reaching a plateau in groups with higher TSC ($P = 0.025$). The same trend was observed in CLBR ($P = 0.01$). On the contrary, miscarriage rates were comparable ranging from 14.7 to 25% ($P = 0.5$).

In order to ascertain possible differences between specific groups regarding CPR, miscarriage rate and CLBR, we performed a post hoc test (Supplementary Table 1).

Outcome in individual TSC groups

Cumulative outcome rates were comparatively assessed in individual TSC groups in relation to different oocyte yield (1 to 5; 6 to 10, > 10). As expected, in the most severe TSC condition ($\leq 0.1 \times 10^6$), average number of embryos were progressively higher ($P < 0.01$) as the number of retrieved oocytes increased (Supplementary Table 2). Equally, CPR (0.0001) (Fig. 1a) and CLBR ($P = 0.008$) (Fig. 1b) also increased in relation to oocyte number. Similar trends were observed in the outcome of groups with TSC values of $> 0.1 \times 10^6$ to 1×10^6 and $> 1 \times 10^6$ to 5×10^6 . In groups characterised by TSC of $> 5 \times 10^6$ to 10×10^6 and $> 10 \times 10^6$ to 39×10^6 , CPR and LBR also seemed to increase in association with a higher number of retrieved oocytes, but such differences were not statistically significant.

Outcome in cycles with different oocyte yield as a function of TSC

Cumulative outcome rates were further investigated, by performing separate analyses in groups of patients with different oocyte yield (1 to 5; 6 to 10, > 10) and adopting TSC as independent variable. In the group where 1 to 5 oocytes were collected, the average number of embryos was not statistically different in the sperm categories $\leq 0.1 \times 10^6$, $> 0.1 \times 10^6$ to 1×10^6 , $> 1 \times 10^6$ to 5×10^6 , $> 5 \times 10^6$ to 10×10^6 , $> 10 \times 10^6$ to 39×10^6 ($P = 0.73$) (Fig. 2 and Supplementary Table 2). On the contrary, CPR ($P = 0.02$) and CLBR ($P = 0.02$) increased significantly with higher TSC values (Fig. 3 a and b and Supplementary Table 2). In the other groups with oocyte yield of oocyte (6 to 10 and > 10) average number of embryos did not vary in dependence of TSC ($P = 0.62$ and $P = 0.57$, respectively) (Supplementary Table 2). Likewise, differences in CPR ($P = 0.48$ and $P = 0.52$, respectively) and CLBR ($P = 0.41$ and $P = 0.28$, respectively) were not significantly different (Fig. 3 a and b).

Table 1 Number of embryos, CPR, and CLBR in cycles selected for female age < 36 years and classified according to TSC

	TSC						P
	< 0.1 × 10 ⁶	> 0.1 × 10 ⁶ –1 × 10 ⁶	1 × 10 ⁶ –5 × 10 ⁶	5 × 10 ⁶ –10 × 10 ⁶	10 × 10 ⁶ –39 × 10 ⁶		
No. of cycles	765	189	144	150	103	179	
Patient age (y), mean ± SD	31.6 ± 2.7	31.5 ± 2.9	31.6 ± 2.9	31.7 ± 2.5	31.9 ± 2.9	31.8 ± 2.7	0.75
No. of retrieved oocytes, mean ± SD	10.1 ± 5.1	10.4 ± 5.5	9.3 ± 5.1	10.5 ± 5.6	10.1 ± 4.6	9.6 ± 4.9	0.185
No. of viable embryos, mean ± SD	3.1 ± 1.9	3.0 ± 1.6	2.8 ± 1.7	3.4 ± 2.2	3.1 ± 1.8	3.2 ± 1.9	0.066
No. of cumulative pregnancies (%)	288 (37.6)	56 (29.6)	48 (33.3)	61 (40.7)	45 (43.7)	78 (43.6)	0.025
No. of miscarriages (%)	51 (17.7)	14 (25)	9 (18.7)	9 (14.7)	7 (15.6)	12 (15.4)	0.5
No. of cumulative live births (%)	237 (31.0)	42 (22.2)	39 (27.1)	52 (34.7)	38 (36.9)	66 (36.9)	0.01

Discussion

Total sperm count has been described as being highly predictive of male health in general [20] and reproduction in particular [21]. Its relative importance in determining the efficacy of IVF treatments remains uncertain and therefore demands thorough assessment, especially in the light of an alarming trend towards a decline observed over the last decades [20]. In this

study, we explored the implications of different values of pre-wash sperm TSC for the clinical outcome in assisted reproduction treatments. To this end, we analysed ICSI cycles performed in women younger than 36 years, to minimise the impact of female age on cycle outcome, while, crucially, TSC was also crossed-analysed with oocyte yield. The overall picture derived from such analysis suggests that better sperm quality, as assessed by higher TSC values, has a positive

Fig. 1 Cumulative outcome rates comparatively assessed in individual TSC groups in relation to different oocyte yield. **a** * $P < 0.0001$, ** $P < 0.0045$, *** $P < 0.0019$. **b** * $P < 0.0085$, ** $P < 0.012$, *** $P < 0.0121$






Fig. 2 Mean (\pm SD) number of embryos in cycles classified according to TSC and subanalysed based on number of retrieved oocytes



impact on cumulative success rates in cycles characterised by few retrieved oocytes, while does not seem to influence the outcome of cycles with a normal or high number of retrieved oocytes. This highlights the importance of the male gamete for the outcome of assisted reproduction treatments, suggesting also a relationship between ovarian response and ability of the oocyte to compensate for paternal-derived deficiencies.

In the perception of reproductive specialists, the overwhelming role of the oocyte in development has overshadowed the importance of the male gamete. This view has been reinforced by the success of ICSI by which virtually all male factors cases, even the most extreme, have become treatable [22], bypassing the first steps of sperm–oocyte interaction at fertilization. Nevertheless, the sperm contribution to

Fig. 3 Cumulative outcome rates comparatively assessed in cycles classified according to number of retrieved oocytes and subanalysed based on TSC. **a** * $P = 0.022$; **b** * $P = 0.017$



the formation of a viable embryo and, after implantation, establishment of a viable pregnancy goes well beyond fertilization. In fact, while sperm are marginally affected by chromosomal aneuploidies, they are not at all immune from other genetic, epigenetic and cellular factors that intervene at postfertilization stages and can compromise the genomic and developmental integrity of the embryo [23]. For example, several studies [24–27], including a previous investigation reported by our group [28, 29], suggest that damage of paternal DNA may not emerge with detectable effects in developmental parameters of the preimplantation embryo or in implantation rates, but can determine an increase in miscarriage rates. Very recently, we have also shown that decreased sperm quality is positively associated with the rate of mosaic blastocysts in cases of preimplantation genetic testing for aneuploidy (PGT-A) [15]. There are, therefore, well-founded reasons to extend our knowledge on the implication of semen quality on reproduction and, in particular, fertility treatments outcome.

To measure the effect of TSC on treatment outcome, we adopted the rates of cumulative pregnancy and live birth as endpoints. Cumulative outcome derived from the use of all viable embryos generated in a single ovarian stimulation cycles has gained progressive importance as a more comprehensive and reliable measure of efficacy in assisted reproduction. In our study, analysis on the overall data set highlighted the importance of TSC in the determination of cumulative outcome, with progressively higher CPR and CLBR associated with higher TSC values. Other parameters were excluded from our analysis and call for an extension of the present study. Further subanalyses revealed other, more intriguing, relationships. Breaking down data according to oocyte yield, the above association was confirmed in cycles with few collected oocytes (1–5), but not in those with a higher number of retrieved oocytes (6–10 and > 10). Of particular note, while the average number of embryos as a function of TSC did not change within each oocyte yield group (1–5, 6–10 and > 10), in cycles with 1–5 retrieved oocytes the CLBR increased five-folds across progressively higher TSC values. At first sight, this inconsistency is puzzling considering the notion that, in the general population, higher rates of cumulative success derive also from a downstream effect of a higher number of embryos generated in a single stimulation cycle. However, taken together, our data may lend credit to an alternative, but not mutually exclusive, hypothesis that in young women a low ovarian response is associated with reduced oocyte quality that in turn may reveal the impact of reduced TSC on clinical outcome. In other words, It may be plausible that in such low response cases compromised sperm function, as suggested in this study by low TSC, might not be compensated for by reparative capacities of the oocyte and therefore might have an impact on development, not necessarily at fertilization or during preimplantation development, but at peri- or postimplantation

stages. Three lines of evidence are relevant to this hypothesis; (i) sperm DNA damage, which is believed to affect assisted reproduction outcome as also reported above [28], was observed to be strongly associated with poor semen quality [30, 31]; (ii) human oocytes express numerous genes involved in DNA repair whose transcripts, abundantly present at the mature stage and during preimplantation development, can intervene to rescue sperm-derived damaged DNA sequences [32, 33]; (iii) the human oocyte transcriptome is affected by a condition of poor ovarian reserve [34]. On the contrary, in cases characterised by normal or high ovarian response, and therefore unaltered oocyte quality according to the above hypothesis, possible sperm defects could be repaired, or compensated for, during early development, preventing significant implications for postimplantation embryo viability. A similar scenario is not merely theoretical. Many studies are in fact consistent with the emerging notion that the detrimental consequences of DNA damage on embryo development depend not only on the magnitude and type of DNA modifications carried over by gametes but also on the reparative abilities of the oocyte [35]. Collectively we are very intrigued by the study outcome. However, we recognise significant limitations of our analysis that should be addressed in future investigations. In fact, while TSC has emerged as an important factor determining clinical outcome in association with poor ovarian response, in a similar fashion other sperm parameters should be assessed, such as morphology and DNA fragmentation.

Conclusions

In final analysis, the present study highlights the general importance of sperm TSC for the efficacy of assisted reproduction treatments. At the same time, it suggests that the consequences of low sperm count on clinical outcome may remain relatively cryptic in association with normal or high ovarian response, but can emerge decisively in case of reduced ovarian response. Moreover, the study is suggestive of new themes for future research. For example, it would be very interesting also from a biological standpoint to assess whether specific oocyte competences, e.g. DNA damage repair that may impact also sperm function at postfertilisation stage are compromised in subject characterised by a reduced ovarian function, irrespective of age.

Funding information The study was self-funded by 9.baby - Family and Fertility Center.

Compliance with ethical standards

Approval for the study was obtained from the local Institutional Review Board. Informed consent was obtained from selected patients.

References

1. Fragouli E, Alfarawati S, Spath K, Jaroudi S, Sarasa J, Enciso M, et al. The origin and impact of embryonic aneuploidy. *Hum Genet*. 2013;132:1001–13.
2. Nagaoka SI, Hodges CA, Albertini DF, Hunt PA. Oocyte-specific differences in cell-cycle control create an innate susceptibility to meiotic errors. *Curr Biol*. 2011;21:651–7.
3. Patrizio P, Bianchi V, Lalioti MD, Gerasimova T, Sakkas D. High rate of biological loss in assisted reproduction: it is in the seed, not in the soil. *Reprod BioMed Online*. 2007;14:92–5.
4. Barratt CL, Kay V, Oxenham SK. The human spermatozoon - a stripped down but refined machine. *J Biol*. 2009;8:63.
5. Jodar M. Sperm and seminal plasma RNAs: what roles do they play beyond fertilization? *Reproduction*. 2019;158(4):R113–23. <https://doi.org/10.1530/REP-18-0639>.
6. Palermo G, Joris H, Devroey P, Van SAC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet*. 1992;340:17–8.
7. Van PA, Proctor ML, Johnson NP, Philipson G. Techniques for surgical retrieval of sperm prior to intra-cytoplasmic sperm injection (ICSI) for azoospermia. *Cochrane Database Syst Rev*. 2008; CD002807.
8. CDC. Assisted Reproductive Technologies 2016. 2018.
9. Germond M, Uner F, Chanson A, Primi MP, Wirthner D, Senn A. What is the most relevant standard of success in assisted reproduction? The cumulated singleton/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA. *Hum Reprod*. 2004;19:2442–4.
10. Garrido N, Bellver J, Remohí J, Simón C, Pellicer A. Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to measuring the likelihood of IVF success. *Fertil Steril*. 2011;96:40–6.
11. Zacà C, Bazzocchi A, Pennetta F, Bonu MA, Coticchio G, Borini A. Cumulative live birth rate in freeze-all cycles is comparable to that of a conventional embryo transfer policy at the cleavage stage but superior at the blastocyst stage. *Fertil Steril*. 2018;110:703–9.
12. Zacà C, Spadoni V, Patria G, Cattoli MC, Bonu MAB, Borini A. How do live birth and cumulative live birth rate in IVF cycles change with the number of oocytes retrieved? *EC Gynecol*. 2017;3:391–401.
13. World Health Organization. WHO laboratory manual for the examination and processing of human semen. 2010.
14. Tarozzi N, Nadalini M, Bizzaro D, Serrao L, Fava L, Scaravelli G, et al. Sperm-hyaluronan-binding assay: clinical value in conventional IVF under Italian law. *Reprod BioMed Online*. 2009;19(Suppl 3):35–43.
15. Tarozzi N, Nadalini M, Lagalla C, Coticchio G, Zacà C, Borini A. Male factor infertility impacts the rate of mosaic blastocysts in cycles of preimplantation genetic testing for aneuploidy. *J Assist Reprod Genet*. 2019;36:2047–55.
16. Borini A, Bonu MA, Coticchio G, Bianchi V, Cattoli M, Flamigni C. Pregnancies and births after oocyte cryopreservation. *Fertil Steril*. 2004;82:601–5.
17. Borini A, Gambardella A, Bonu MA, Dal PL, Sciajno R, Bianchi L, et al. Comparison of IVF and ICSI when only few oocytes are available for insemination. *Reprod BioMed Online*. 2009;19:270–5.
18. Borini A, Bafaro MG, Bianchi L, Violini F, Bonu MA, Flamigni C. Oocyte donation programme: results obtained with intracytoplasmic sperm injection in cases of severe male factor infertility or previous failed fertilization. *Hum Reprod*. 1996;11:548–50.
19. Cobo A, Bellver J, Domingo J, Pérez S, Crespo J, Pellicer A, et al. New options in assisted reproduction technology: the Cryotop method of oocyte vitrification. *Reprod BioMed Online*. 2008;17:68–72.
20. Levine H, Jørgensen N, Martino-Andrade A, Mendiola J, Weksler-Derri D, Mindlis I, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. *Hum Reprod Update*. 2017;23:646–59.
21. Wang C, Swerdloff RS. Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests. *Fertil Steril*. 2014;102:1502–7.
22. Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. *Semin Reprod Med*. 2009;27:165–70.
23. Rumbold AR, Sevoyan A, Oswald TK, Fernandez RC, Davies MJ, Moore VM. Impact of male factor infertility on offspring health and development. *Fertil Steril*. 2019;111:1047–53.
24. Yuan M, Huang L, Leung WT, Wang M, Meng Y, Huang Z, et al. Sperm DNA fragmentation valued by SCSA and its correlation with conventional sperm parameters in male partner of recurrent spontaneous abortion couple. *Biosci Trends*. 2019;13:152–9.
25. Deng C, Li T, Xie Y, Guo Y, Yang QY, Liang X, et al. Sperm DNA fragmentation index influences assisted reproductive technology outcome: a systematic review and meta-analysis combined with a retrospective cohort study. *Andrologia*. 2019;51:e13263.
26. Kamkar N, Ramezani F, Sabbaghian M. The relationship between sperm DNA fragmentation, free radicals and antioxidant capacity with idiopathic repeated pregnancy loss. *Reprod Biol*. 2018;18:330–5.
27. Tarozzi N, Nadalini M, Stronati A, Bizzaro D, Dal PL, Coticchio G, et al. Anomalies in sperm chromatin packaging: implications for assisted reproduction techniques. *Reprod BioMed Online*. 2009;18:486–95.
28. Borini A, Tarozzi N, Bizzaro D, Bonu MA, Fava L, Flamigni C, et al. Sperm DNA fragmentation: paternal effect on early post-implantation embryo development in ART. *Hum Reprod*. 2006;21:2876–81.
29. Garolla A, Cosci I, Bertoldo A, Sartini B, Boudjema E, Foresta C. DNA double strand breaks in human spermatozoa can be predictive for assisted reproductive outcome. *Reprod BioMed Online*. 2015;31:100–7.
30. Evgeni E, Lymberopoulos G, Touloupidis S, Asimakopoulos B. Sperm nuclear DNA fragmentation and its association with semen quality in Greek men. *Andrologia*. 2015;47:1166–74.
31. Evgeni E, Lymberopoulos G, Gazouli M, Asimakopoulos B. Conventional semen parameters and DNA fragmentation in relation to fertility status in a Greek population. *Eur J Obstet Gynecol Reprod Biol*. 2015;188:17–23.
32. Jaroudi S, Kakourou G, Cawood S, Doshi A, Ranieri DM, Serhal P, et al. Expression profiling of DNA repair genes in human oocytes and blastocysts using microarrays. *Hum Reprod*. 2009;24:2649–55.
33. Menezo YJ, Russo G, Tosti E, El MS, Benkhalifa M. Expression profile of genes coding for DNA repair in human oocytes using pangenomic microarrays, with a special focus on ROS linked decays. *J Assist Reprod Genet*. 2007;24:513–20.
34. Barragán M, Pons J, Ferrer-Vaquer A, Cornet-Bartolomé D, Schweitzer A, Hubbard J, et al. The transcriptome of human oocytes is related to age and ovarian reserve. *Mol Hum Reprod*. 2017;23:535–48.
35. Stringer JM, Winship A, Liew SH, Hutt K. The capacity of oocytes for DNA repair. *Cell Mol Life Sci*. 2018;75:2777–92.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.